CDT Equity files amended 8-K for Sarborg investment; Sarborg 2025 revenue $4.6M, net loss $508K

CDT Equity Inc.

Sarborg FY2025 revenue $4.6M, gross profit $4.2M, net loss $508K (vs. $98K revenue, $282K loss in 2024).
Sarborg had $10K cash and $790K accumulated deficit at 12/31/25; going-concern doubt mitigated by founder guaranty.
CDT's initial investment in Sarborg completed; audited financials and unaudited pro forma statements now filed as Exhibits 99.1/99.2.
Sarborg is an agentic AI platform for drug repurposing and industrial signature analysis; material related-party revenue and deferred revenue.
CDT's common stock (CDT) and warrants (CDTTW) trade on Nasdaq; no deal terms or acquisition price disclosed in this amendment.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.